HOSPITAL DR. PILA
1. Target Overview & Investment Thesis
HOSPITAL DR. PILA is a 115-bed under-performing / distressed in nan, PR with $43.3M in net patient revenue and a -5.7% operating margin. The hospital serves a payer mix of 6.6% Medicare, 19.7% Medicaid, and 73.7% commercial.
Thesis: Undervalued. Our ML models identify $3.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -5.7% to 1.7% (+736bps).
| Net Revenue HCRIS | $43.3M |
| Current EBITDA COMPUTED | $-2.5M |
| Operating Margin COMPUTED | -5.7% |
| Occupancy HCRIS | 45.4% |
| Revenue / Bed COMPUTED | $377K |
| Net-to-Gross HCRIS | 61.9% |
| Distress Probability ML | 57.0% |
2. Market Context & Competitive Position
PR has 61 Medicare-certified hospitals with a median operating margin of -8.8%. The target's margin of -5.7% places it above the state median. Among 40 size-comparable peers (58-230 beds), the median margin is -9.7%. The target performs in line with or above peers.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (58-230), prioritizing same-state peers. 40 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| HOSPITAL DR. PILA (Target) | PR | 115 | $43.3M | -5.7% |
| HOSPITAL MENONITA DE CAYEY | PR | 225 | $186.2M | 15.0% |
| ADMIN DE SERVICIOS MEDICOS DE | PR | 65 | $179.7M | -50.0% |
| MAYAGUEZ MEDICAL CENTER | PR | 210 | $102.8M | 7.6% |
| HOSPITAL PAVIA SANTURCE | PR | 156 | $101.9M | -9.4% |
| UNIVERSITY DISCTRICT HOSPITAL | PR | 210 | $97.4M | -43.2% |
| HOSPITAL MENONITA AIBONITO | PR | 129 | $92.1M | -3.1% |
| HOSPITAL DE LA CONCEPCION | PR | 167 | $91.0M | -3.9% |
| BAYAMON MEDICAL CENTER | PR | 207 | $81.7M | 0.6% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.2M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $910K | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $867K | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $858K | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $527K | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $28K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-2.5M |
| + RCM Uplift | +$3.2M |
| Pro Forma EBITDA | $729K |
| Current Margin | -5.7% |
| Pro Forma Margin | 1.7% |
| WC Released (1x) | $1.7M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-3.8M | $15.7M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-3.8M | $16.0M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-3.4M | $25.3M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-3.4M | $26.6M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-4.2M | $946K | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-4.2M | $-311K | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| High | Elevated distress probability | Model estimates 57.0% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 40 hospitals with 58-230 beds
- Same-state prioritization (n=41)
- Comp margins: P25=-21.4% / P50=-9.7% / P75=-2.0%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.